Clinical Trials
461
47 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1881
Active, not recruiting
14
3.0%
Completed
264
57.3%
Enrolling By Invitation
4
0.9%
Not yet recruiting
29
6.3%
Recruiting
48
10.4%
Suspended
2
0.4%
Terminated
9
1.9%
Unknown
84
18.2%
Withdrawn
7
1.5%
No approval data available
- A University of Nottingham-led study published in BMC Biology identifies the lemon frost leopard gecko as a novel animal model for studying cancer, with tumors appearing naturally in approximately 80% of individuals. - Whole-genome sequencing revealed recurring genetic changes in gecko tumors that affect the same genes and biological pathways implicated in human cancers. - Unlike laboratory mice that require tumor induction, lemon frost geckos develop aggressive, metastatic tumors at a relatively young age, offering a rare window into natural cancer progression. - Researchers emphasize that studying species across the tree of life, including cancer-susceptible and cancer-resistant animals, could inspire new strategies for cancer prevention, detection, and treatment in humans.
- Neupulse raised £3 million in funding led by Eos Advisory and Midlands Engine Investment Fund II to accelerate development of its non-drug wristband device for Tourette Syndrome management. - The neurotherapeutics company plans to launch its wearable neuromodulation technology commercially in mid-2026, addressing critical gaps in current treatment options for the condition. - Tourette Syndrome affects up to 2% of children worldwide, with current treatments limited to medication and behavioral therapy, neither considered ideal solutions by investors. - The funding will support product development, regulatory progress, and early commercialization efforts as the company transitions from development to market launch.
- A large cohort study of 109,504 gout patients found that achieving serum urate levels below 6 mg/dL within 12 months of starting urate-lowering therapy reduced major adverse cardiovascular events by 9%. - Patients who reached the target urate level demonstrated higher 5-year event-free survival rates (89.4% vs 88.3%) compared to those who did not achieve the target. - The cardiovascular benefit was most pronounced in high-risk patients and those achieving even lower urate levels below 5 mg/dL, who showed a 23% relative risk reduction. - The findings provide additional evidence supporting treat-to-target urate-lowering strategies in gout management, particularly for patients with elevated cardiovascular risk profiles.
- Scientists from the University of Nottingham have developed a breakthrough protein-based gel that can regenerate tooth enamel through epitaxial mineralization, forming new mineral deposits that fuse with existing tissue. - The biomimetic elastin-like recombinamer (ELR) gel demonstrated superior resistance to wear, fracture and acid attack compared to natural enamel in laboratory tests using extracted human molars. - The single-application treatment could transform dental care by enabling biological repair of enamel erosion and cavities, with the startup company Mintech-Bio planning to launch the first product next year.
- Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics. - The breakthrough provides critical insights into LNP composition that could lead to more efficient and safer formulations for treating diseases including cystic fibrosis, pulmonary fibrosis, and COPD. - This new analytical method may improve quality control during manufacturing scale-up, potentially accelerating the translation of LNP-based therapies from laboratory to clinical applications.
- Precision medicine company Oncimmune Holdings has entered administration after failing to secure a buyer for its German subsidiary or raise additional capital to meet short-term funding needs. - The University of Nottingham spin-out has requested suspension of its shares on the AIM market, with trading halted as of March 17, 2025, following a 93% stock value decline over the past year. - Alvarez & Marsal Europe LLP managing directors will be appointed as administrators to preserve remaining business value for creditors, marking a significant setback for the autoantibody profiling services provider.
- University of Nottingham initiates groundbreaking TrueBlue trial using AI and virtual avatar technology to detect early-stage postnatal depression, offering a modern alternative to traditional clinical scales. - The 12-week study features an innovative virtual human avatar named Kiera, guiding participants through tasks to monitor mood patterns and enable earlier detection of mood disorders. - The trial offers flexible participation options, allowing subjects to engage either in-person at the Institute of Mental Health or completely online, prioritizing convenience and accessibility.
- The upcoming TERZO trial will assess duvelisib against standard chemotherapy in patients with nodal T-cell lymphoma with follicular helper T phenotype, addressing a significant treatment gap in rare lymphomas. - Phase 2 PRIMO study demonstrated promising results with duvelisib showing a 48% overall response rate and 33.3% complete response rate in relapsed/refractory PTCL patients. - The TERZO trial aims to enroll 124 patients across EU and UK, with progression-free survival as the primary endpoint, potentially leading to regulatory approval if successful.
• The phase 3 FALCON trial's final overall survival (OS) analysis showed no significant difference between fulvestrant and anastrozole in endocrine therapy-naive, HR-positive advanced breast cancer. • Median OS was 44.8 months for fulvestrant versus 42.7 months for anastrozole (HR, 0.97; P = .76), with a median follow-up of 37.1 months. • A trend toward improved survival with fulvestrant was observed in patients with nonvisceral disease (median OS 65.2 months vs 47.8 months; HR, 0.85). • Post-hoc analysis revealed greater OS improvement with fulvestrant in nonvisceral vs. visceral disease subgroups compared to anastrozole.
• A new study suggests GLP-1 receptor agonists (GLP-1 RAs) may reduce alcohol consumption by targeting the brain's reward center. • The effect was more pronounced in heavy drinkers with obesity (BMI over 30), indicating a potential therapeutic benefit in this population. • Clinical trials and observational studies showed GLP-1 RA use was associated with reduced alcohol consumption and fewer alcohol-related health issues. • These findings suggest GLP-1 RAs could be a future treatment option for excessive alcohol use, potentially reducing alcohol-related deaths.
